Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.46 |
| ▸ | NNMT | P40261 | 3/20 | 0.45 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | CFTR | P13569 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | GLA | P06280 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31663021 | 1.00 | NPSR1 (0.47) | NPSR1KDM4EALDH1A1NNMTPKM | |
| SCHEMBL3058519 | 0.84 | TDP1 (0.51) | KDM4EALDH1A1NNMTPOLBTDP1 | |
| SCHEMBL14358203 | 0.84 | NNMT (0.54) | ALDH1A1NNMTPOLBTDP1GAA | |
| SCHEMBL1315299 | 0.83 | MAPK8 (0.43) | NPSR1KDM4EALDH1A1PKMTDP1 | |
| SCHEMBL31253850 | 0.83 | NNMT (0.42) | KDM4EALDH1A1NNMTPOLBTDP1 | |
| SCHEMBL30775571 | 0.82 | NPSR1 (0.47) | NPSR1KDM4EALDH1A1PKMHSD17B10 | |
| SCHEMBL320590 | 0.82 | NPSR1 (0.47) | NPSR1KDM4EALDH1A1PKMHSD17B10 | |
| SCHEMBL25179981 | 0.80 | NPSR1 (0.48) | NPSR1KDM4EALDH1A1NNMTPKM | |
| SCHEMBL262928 | 0.80 | GRM5 (0.54) | NPSR1KDM4EALDH1A1PKMHSD17B10 | |
| SCHEMBL30775059 | 0.80 | GRM5 (0.54) | NPSR1KDM4EALDH1A1PKMHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250368647-A1 | NITROGEN CONTAINING CONDENSED 2,3-DIHYDROQUINAZOLINONE COMPOUNDS AS NAV1.8 INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2025-12-04 | — | — | US | disclosed |
| EP-4536660-A1 | NITROGEN CONTAINING CONDENSED 2,3-DIHYDROQUINAZOLINONE COMPOUNDS AS NAV1.8 INHIBITORS | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2025-04-16 | — | — | EP | disclosed |
| CN-119325476-A | Nitrogen-containing condensed 2, 3-dihydroquinazolinone compounds as NAV1.8 inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2025-01-17 | — | — | CN | disclosed |
| WO-2023238065-A1 | NITROGEN CONTAINING CONDENSED 2,3-DIHYDROQUINAZOLINONE COMPOUNDS AS NAV1.8 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-12-14 | — | — | WO | disclosed |
| US-9458170-B2 | Compound of camptothecin and preparation and use thereof | YULIANG LI (CN) | 2016-10-04 | — | — | US | disclosed |
| US-9458170-B2 | Compound of camptothecin and preparation and use thereof | YULIANG LI (CN) | 2016-10-04 | — | — | US | disclosed |
| US-9458170-B2 | Compound of camptothecin and preparation and use thereof | YULIANG LI (CN) | 2016-10-04 | — | — | US | disclosed |
| US-20150166559-A1 | COMPOUND OF CAMPTOTHECIN AND PREPARATION AND USE THEREOF | Li, Yuliang (CN) | 2015-06-18 | — | — | US | disclosed |
| US-20150166559-A1 | COMPOUND OF CAMPTOTHECIN AND PREPARATION AND USE THEREOF | Li, Yuliang (CN) | 2015-06-18 | — | — | US | disclosed |
| US-20150166559-A1 | COMPOUND OF CAMPTOTHECIN AND PREPARATION AND USE THEREOF | Li, Yuliang (CN) | 2015-06-18 | — | — | US | disclosed |
| EP-2862571-A1 | COMPOUND OF CAMPTOTHECIN AND PREPARATION AND USE THEREOF | Li, Yuliang (MN) | 2015-04-22 | — | — | EP | disclosed |
| EP-2862571-A1 | COMPOUND OF CAMPTOTHECIN AND PREPARATION AND USE THEREOF | Li, Yuliang (MN) | 2015-04-22 | — | — | EP | disclosed |
| US-20090181968-A1 | Novel 3-Bicyclocarbonylaminopyridine-2-Carboxamides or 3-Bicyclocarbonylaminopyrazine-2-Carboxamides | ASTRAZENECA AB (SE) | 2009-07-16 | — | — | US | disclosed |
| US-20090181968-A1 | Novel 3-Bicyclocarbonylaminopyridine-2-Carboxamides or 3-Bicyclocarbonylaminopyrazine-2-Carboxamides | ASTRAZENECA AB (SE) | 2009-07-16 | — | — | US | disclosed |
| US-20090181968-A1 | Novel 3-Bicyclocarbonylaminopyridine-2-Carboxamides or 3-Bicyclocarbonylaminopyrazine-2-Carboxamides | ASTRAZENECA AB (SE) | 2009-07-16 | — | — | US | disclosed |
| CN-101336238-A | Novel bicyclic carbonylaminopyridine-2-carboxamides or 3-bicyclic carbonylaminopyrazine-2-carboxamides | ASTRAZENECA AB (SE) | 2008-12-31 | — | — | CN | disclosed |
| EP-1957478-A2 | NEW COMPOUNDS | AstraZeneca AB (SE) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007061360-A2 | NOVEL 3-BICYCLOCARBONYLAMINOPYRIDINE-2-CARBOXAMIDES OR 3-BICYCLOCARBONYLAMINOPYRAZINE-2-CARBOXAMIDES | ASTRAZENECA AB (SE) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007061360-A2 | NOVEL 3-BICYCLOCARBONYLAMINOPYRIDINE-2-CARBOXAMIDES OR 3-BICYCLOCARBONYLAMINOPYRAZINE-2-CARBOXAMIDES | ASTRAZENECA AB (SE) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166559-A1 | COMPOUND OF CAMPTOTHECIN AND PREPARATION AND USE THEREOF | TOP2A, TOP2B, TYMP | NPSR1 4625/4885KDM4E 4067/4885ALDH1A1 1386/4885 |
| US-20250368647-A1 | NITROGEN CONTAINING CONDENSED 2,3-DIHYDROQUINAZOLINONE COMPOUNDS AS NAV1.8 INHIBITORS | SCN8A, SCN2A, SCN5A | NPSR1 1536/4885KDM4E 2636/4885ALDH1A1 2933/4885 |
| US-20090181968-A1 | Novel 3-Bicyclocarbonylaminopyridine-2-Carboxamides or 3-Bicyclocarbonylaminopyrazine-2-Carboxamides | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNA2, CNR2 | NPSR1 1379/4885KDM4E 1638/4885ALDH1A1 542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.